(Q34329548)

1 August 2017

1 reference

title

Oncolytic viruses as therapeutic agents (English)

1 reference

1 August 2017

1 reference

Wildner O

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

33

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

291-304

1 reference

Studies on the use of viruses in the treatment of carcinoma of the cervix

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Treatment of human cancer with mumps virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Newcastle disease virus selectively kills human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Herpes simplex 1716--an ICP 34.5 mutant--is severely replication restricted in human skin xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Poxvirus vectors: orphaned and underappreciated

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Interaction of adenoviral E4 and E1b products in late gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Host-range mutants of adenovirus type 5 defective for growth in HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Complementary adenoviral vectors for oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

21 January 2018

Herpes simplex viruses

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Differentiation of the shutoff of protein synthesis by virion host shutoff and mutant gamma (1)34.5 genes of herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

The preferential cytotoxicity of reovirus for certain transformed cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Reovirus-induced apoptosis is mediated by TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Antineoplasic activity of parvoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Development and mechanisms of interferon resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Viral escape from immune recognition: multiple strategies of adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Gene therapy for cancer: what have we done and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

The effect of ganciclovir on herpes simplex virus-mediated oncolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853890109002081

10.3109/07853890109002081

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference